News

Press Release
April 15, 2026

GNQ Insilico Plans to Accelerate Precision Medicine and Clinical AI Adoption Across Drug Development and Patient Care

The new service offering combines GNQ Insilico’s Causal AI Drug Assessment, Drug Simulation, and Digital…
Read More
Press Release
March 16, 2026

GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC)

IB Acquisition Corp. Mon, March 16, 2026 at 1:45 PM EDT 12 min read  …
Read More
Press Release
October 30, 2025

GNQ Insilico Secures MindLab, an Award Winning Pharma Company, as a Client for its Drug Assessment Platform

GNQ Insilico's Quantum-enhanced and AI-powered Platform to Accelerate Development of MindLab's Novel Pain Management Therapy…
Read More
Press Release
September 10, 2025

GNQ Insilico Launches Revolutionary AI-Driven Assessment Platform to Transform Precision Medicine and Drug Development

lti-Agentic AI Platform Powered by Proprietary Systems Biology Engine Delivers Personalized Therapy Optimization and Investment…
Read More
Press Release
July 9, 2025

GNQ Insilico Unveils Multi-Pathway Therapeutic Formulation for ALS Leveraging proprietary Drug Assessment Platform

GNQ Insilico, Inc. (“GNQ” or “the Company”), a cutting-edge TechBio platform company, announced results from…
Read More
Press Release
July 7, 2025

GNQ’s Drug Assessment Platform Enhances Non-Small Cell Lung Cancer Treatment by Extending Efficacy Beyond Universal Resistance Barrier

GNQ Insilico, Inc. (“GNQ” or “the Company”), a TechBio platform company, demonstrated the advanced capabilities…
Read More
Press Release
December 15, 2024

GNQ presents at Quantum Rising Conference alongside Deloitte & IBM Quantum

Sudhir Saxena, Chief Technology Officer of GNQ Insilico, Inc. (GNQ), was invited by Deloitte Consulting…
Read More
Press Release
June 18, 2024

GNQ Insilico’s AI-Driven Digital Twins Platform Shows Promising Results in Simulating Effects of a Drug on Synthesized Digital Twins

GNQ Insilico’s AI-Driven Digital Twins Platform Shows Promising Results in Simulating Effects of a Drug…
Read More
Press Release
March 30, 2024

GNQ Unveils AI-Powered Platform Prototype Delivering 128% AUC Improvement in Personalized Clomiphene Dosing Optimization

GNQ Insilico, Inc. (“GNQ” or “the Company”), a TechBio platform company, announced the successful development…
Read More
Press Release
March 4, 2024

GNQ Insilico Announces Collaboration with Fortune 100 Company to Develop Next-Generation Clinical Trial Platform

SAN FRANCISCO, CALIFORNIA, USA, March 4, 2024 /EINPresswire.com/ — GNQ Insilico Inc. (“GNQ”), a company…
Read More
Press Release
April 15, 2026

GNQ Insilico Plans to Accelerate Precision Medicine and Clinical AI Adoption Across Drug Development and Patient Care

The new service offering combines GNQ Insilico’s Causal AI Drug Assessment, Drug Simulation, and Digital…
Read More
Press Release
March 16, 2026

GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC)

IB Acquisition Corp. Mon, March 16, 2026 at 1:45 PM EDT 12 min read  …
Read More
Press Release
October 30, 2025

GNQ Insilico Secures MindLab, an Award Winning Pharma Company, as a Client for its Drug Assessment Platform

GNQ Insilico's Quantum-enhanced and AI-powered Platform to Accelerate Development of MindLab's Novel Pain Management Therapy…
Read More
Press Release
September 10, 2025

GNQ Insilico Launches Revolutionary AI-Driven Assessment Platform to Transform Precision Medicine and Drug Development

lti-Agentic AI Platform Powered by Proprietary Systems Biology Engine Delivers Personalized Therapy Optimization and Investment…
Read More
Press Release
July 9, 2025

GNQ Insilico Unveils Multi-Pathway Therapeutic Formulation for ALS Leveraging proprietary Drug Assessment Platform

GNQ Insilico, Inc. (“GNQ” or “the Company”), a cutting-edge TechBio platform company, announced results from…
Read More